$X_1X_2X_3$

wherein:

X_2 is any amino acid sequence of from 10 to [100] 50 residues derived from, homologous to or contiguous within amino acids 506 to 518 inclusive or derivatives thereof of human GAD65 [and/or] or amino acids 24 to 36 inclusive or derivatives thereof of human proinsulin; wherein when X_1 or X_2 comprise naturally occurring amino acid residues then no more than five contiguous amino acid residues are derived from human proinsulin or GAD65 and wherein said peptide [molecule] or chemical equivalent thereof is capable of reacting with T cells and modifying T-cell function when incubated with cells from subjects with pre-clinical or clinical Insulin-Dependent Diabetes Mellitus (IDDM).

Claim 5, line 2, after "FFYTPKTRREAED" and before the period, insert --(SEQ ID NO:1)--.

Claim 6, line 2, after "FWYIPPSLRTLED" and before the period, insert --(SEQ ID NO:2)--.

Claim 7, line 7, after "FFYTPKTRREAED" insert --(SEQ ID NO:1)--.

Claim 7, line 7, after "FWYIPPSLRTED" insert --(SEQ ID NO:2)--.

Claim 34, line 2, after "FFYTPKTRREAED" and before the period, insert --(SEQ ID NO:1)--.

Claim 35, line 2, after "FWYIPPSLRTLED" and before the period, insert --(SEQ ID NO:2)--.